Jantoven Warfarin Recall Issued Due to Mislabeled Bottles

A recall of Jantoven, a form of Warfarin, has been issued due to a risk that some bottles may contain pills that are more potent than what is listed on the blood thinner’s label. 

The FDA and drug maker Upsher-Smith Laboratories announced the Jantoven Warfarin recall on Thursday, after at least one bottle was found to contain pulls that were three times more stronger than what was listed on the bottle’s label. The mislabeled bottle of Jantoven Warfarin Sodium was found to contain 10mg tablets when bottle indicated it contained 3mg tablets.

The FDA and the manufacturer warn that a blood thinner overdose of Jantoven could result in serious and potentially fatal bleeding in patients. There have been no reports of injuries or illnesses, and so far only the one bottle has been found to contain the wrong pills.

Jantoven is a form of warfarin, an anticoagulant which has been approved for use in the U.S. since the early 1950s. It is the most commonly used anticoagulant in the United States and is also sold under the brand names Coumadin, Marevan, Lawarin and Waran. It is also sold as a generic.

The recall affects Jantoven Warfarin Sodium, USP, 3mg Tablets from lot #284081. The pills have an expiration date of September 2012 and an NDC number of 0832-1214-00.

The 3mg tablets are tan and have an imprint of the letters WRF above a line in the middle of the pill and the number 3 imprinted below the line. The reverse side of the 3mg tablets is imprinted with the number 832. The 10mg tablets are white, have WRF imprinted above a line in the middle of the pill and the number 10 imprinted below the line and also has the number 832.

Patients with questions can call the Upsher-Smith medical information line at 1-888-650-3789.